USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ALTUS BIOLOGICS, INC.
Address:
ALTUS BIOLOGICS, INC.
625 PUTNAM AVE
CAMBRIDGE, MA 02139 0480
Phone:
(617) 299-2971
URL:
N/A
EIN:
43573277
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $701,807.00 9
SBIR Phase II $1,995,476.00 3

Award List:

Dehydrogenase Crystals as Catalysts in Organic Synthesis

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Alexey Margolin
Abstract:
N/a

Crosslinked Enzyme Crystals Deposited on Surfaces as a Novel Type of Catalyst for Large Scale Chemical

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$65,000.00
Agency:
NSF
Principal Investigator:
Alexey Margolin
Abstract:
N/a

Dehydrogenase Crystals as Catalysts in Organic Synthesis

Award Year / Program / Phase:
1996 / SBIR / Phase II
Award Amount:
$495,146.00
Agency:
HHS
Principal Investigator:
Alexey Margolin
Abstract:
Enzyme microcrystals (less than 100 um) grown from aqueous solution and cross-linked witha bifunctional agent such as glutaraldehyde exhibit remarkable characteristics that are superior to bothsoluble and conventionally immobilized enzymes. Such cross-linked enzyme crystals (CLECs) remainactive in… More

SBIR Phase I: Protein Crystals as Novel Materials for Chromatography

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
NSF
Principal Investigator:
Alexey Margolin
Abstract:
N/a

PROTEIN DRUG DELIVERY BASED ON STABILIZED PROTEIN

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Margolin, alexey l
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Margolin alexey l
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
NSF
Principal Investigator:
James Lalonde
Abstract:
N/a

PROTEASE FORMULATION BASED ON CROSSLINKED ENZYME CRYSTAL

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,083.00
Agency:
HHS
Principal Investigator:
Bhami C. Shenoy
Abstract:
Design of new efficient drug delivery systems for proteins is one of the major themes of modern biotechnology and biopharmaceutical industry. We found that crosslinked enzyme crystals (CLECs(R)) show stability under low pH, on storage and against proteolysis. The CLECs can be prepared in high yield… More

NOVEL ENZYME FORMULATION FOR TREATMENT OF HYPEROXALURIA

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$86,724.00
Agency:
HHS
Principal Investigator:
Bhami C. Shenoy
Abstract:
DESCRIPTION (provided by applicant): Design of new efficient drug delivery systems for proteins is one of the major themes of modern biotechnology and biopharmaceutical industry. We found that crosslinked enzyme crystals (CLECs) show stability under low pH, on storage and… More

PREVENTION OF BIOFILMS IN MEDICAL DEVICES

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Design of new efficient drug delivery systems for proteins is one of the major themes of modern biotechnology and biopharmaceutical industry. We found that cross-linked enzyme crystals (CLECs) show remarkable stability at various pHs, on storage, against… More

NOVEL PROTEASE FORMULATION BASED ON CROSSLINKED CRYSTALS

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Design of stable and efficient formulation of proteins for therapeutic use as drugs has been a major focus of biotechnology and pharmaceutical companies. In the Phase I grant, we developed a stable, active formulation of protease from Aspergillus melleus,… More

NOVEL PROTEASE FORMULATION BASED ON CROSSLINKED CRYSTALS

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$750,330.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Design of stable and efficient formulation of proteins for therapeutic use as drugs has been a major focus of biotechnology and pharmaceutical companies. In the Phase I grant, we developed a stable, active formulation of protease from Aspergillus melleus,… More